Abstract

Abstract Purpose: There are documented ethnic disparities in cancer care access, use and clinical outcomes in North America; however, the role of ethnicity on different outcomes of unrelated donor hematopoietic stem cell transplantation (HSCT) as an established treatment for many hematological and non-hematological malignancies has not been studied for Canadian patients. Patients and Methods: We reviewed the registry data of 395 patients receiving first time unrelated donor HSCT for hematological malignancies at leukemia/BMT center of British Columbia (BC) between 1988 and 2008. They were reported to be white (N=340), Asian (N=32), native (N=8), Hispanic (N=3), black (N=2), mixed (N=9) and other- not specified (N=1) which were further categorized as white (N=340) and non-white (N=55). Different HSCT outcomes were compared by log-rank test and Cox proportional hazard regression adjusting for significant patient, disease and transplant related factors at 95% significance level. Results: Univariate and multivariate analysis didn't show any statistically significant difference for overall survival, disease-free survival, relapse, acute graft versus host disease (aGVHD) grade 2+ and chronic graft versus host disease (cGVHD) rates between whites and non-whites. We reanalyzed a subset of 115 cases (88 whites and 27 non-whites) who received their HSCT after June 2001 (start date for application of high resolution DNA-based HLA matching in the study center) and their underlying diagnosis was acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia and myelodysplastic syndrome. The results showed a higher risk of cGVHD for non-whites in univariate analysis (HR1.82, 95% CI1.07-3.12, P=0.03), however; adjusting for covariates in the multivariate analysis resolved this difference (P = 0.09). Conclusion: According to our data, HSCT clinical outcomes are comparable between white and non-white ethnic minorities in BC. The contrasting result with that of US studies might be due to different ethnic composition of BC and using a heterogeneous non-white ethnic group as the comparator (to increase the power of study) which could mask any unsought differences in the subgroups. Citation Information: Cancer Epidemiol Biomarkers Prev 2010;19(10 Suppl):B77.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call